Healthcare / Medical Instruments & SuppliesBSE
$235.00
+4.95 (+2.15%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-66.1M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
53/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.0B
P/E
44.6x
↑EV/EBITDA
28.1x
↑ROE
11.9%
↑Gross Margin
69.7%
↑Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+19.5%
FCF CAGR
—
FCF margin
-8.6%
FCF / Net income
-0.81x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.72B · net income $289.8M · FCF $-233.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.72B | $2.72B | $2.37B | $1.91B | $1.59B |
| Net Income | $289.8M | $289.8M | $317.7M | $247.8M | $-39.7M |
| EBITDA | $461.7M | $461.7M | $522.4M | $254.2M | $108.3M |
| EPS | 5.26 | 5.26 | 6.05 | 4.51 | -0.72 |
| Gross Margin | 69.7% | 69.7% | 75.8% | 74.7% | 73.2% |
| Operating Margin | 10.1% | 10.1% | 11.4% | 7.8% | 0.1% |
| Net Margin | 10.7% | 10.7% | 13.4% | 12.9% | -2.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.09 | 1.17 | 2.18 |
| Current Ratio | 6.13 | 6.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-233.7M | $-233.7M | $277.5M | $-66.1M | $44.6M |
| Returns | |||||
| ROE | 11.9% | 11.9% | 15.2% | 58.3% | -22.3% |
| Valuation | |||||
| P/E | 44.59 | 44.59 | 64.51 | — | — |
| EV/EBITDA | 28.14 | 28.14 | 37.87 | — | — |
| P/B | 5.32 | 5.32 | 9.83 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 14.8% | 14.8% | 23.6% | 20.5% | — |
| EPS Growth | -13.1% | -13.1% | 34.2% | 723.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
58.3%
EPS terminal req.
$20.85
Spread vs growth
-71.3%
5Y implied EPS CAGR
36.8%
EPS terminal req.
$25.23
Spread vs growth
-49.9%
10Y implied EPS CAGR
22.7%
EPS terminal req.
$40.64
Spread vs growth
-35.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.0%
Start / end P/E
65.9x → 44.7x
EPS bridge
6.05 → 5.26
Residual
+4.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.